News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health's CEO Lisa Conte will participate in a virtual fireside chat on June 10, 2025 to discuss the company's orphan disease development programs -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Jaguar Health, Inc. announces purchase of 246,306 shares of common stock at $6.09 per share in a registered direct offering. H.C. Wainwright & Co. serves as exclusive placement agent -
-
-
COMMUNIQUÉ DE PRESSE
First Patient Randomized in Jaguar Health’s Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)
Jaguar Health's crofelemer shows promise in reducing total parenteral support in pediatric MVID patient. Ongoing trials and future expectations discussed -
